Open access
Sep 2026
3 Safety Profile of Casdatifan Monotherapy in Patients with Clear Cell Renal Cell Carcinoma: Pooled Analysis of the ARC-20 Study (NCT05536141)
Abstract Background Hypoxia-inducible factor 2α (HIF-2α) is highly dysregulated in clear cell renal cell carcinoma (ccRCC), resulting in increased expression of proteins involved with angiogenesis, proliferation, and metastasis. Casdatifan is a potent, selective, orally bioavailable HIF-2α inhibitor that has demonstrat...
R. McKay, J. Merchan, A. Patnaik et al.
· The Oncologist · 0 citations